Stock Scorer

Amylyx Pharmaceuticals, Inc. (AMLX)

Amylyx Pharmaceuticals, Inc. reported revenue of 0 USD for the quarter ending 31 December 2025.

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than filled in. Quarters are the company's own, counted from its financial year ending 12-31. Amounts in USD. The same series drawn ›

As last reported

The newest period the filing supports for each figure, in USD.
FigurePeriodAmountYear on year
Revenue Q4 '25 · ending 31 December 2025 0 —
Gross Profit Q4 '25 · ending 31 December 2025 0 —
Operating Income Q2 '26 · ending 30 June 2026 -45.7M —
Net Income Q2 '26 · ending 30 June 2026 -43.4M —
Cost of Revenue Q4 '25 · ending 31 December 2025 0 —
Operating Cash Flow Q2 '26 · ending 30 June 2026 -31.4M —
Free Cash Flow Q4 '25 · ending 31 December 2025 -28M —
Shares Outstanding Q2 '26 · ending 30 June 2026 111.2M +29.8%
EPS Q2 '26 · ending 30 June 2026 -1.41 —

Revenue and profit by financial year

As filed, in USD. A year the filing does not support is not listed.
YearEnding RevenueOperating IncomeNet IncomeFree Cash Flow
20252025-12-31 0-153.3M-144.7M-123.5M
20242024-12-31 87.4M-314.7M-301.7M-167.8M
20232023-12-31 380.8M38.8M49.3M10.7M
20222022-12-31 22.2M-201.3M-198.4M-182.4M
20212021-12-31 285K-82.7M-87.9M-75.2M

Every period

Revenue Quarterly

PeriodEndingRevenue
Q4 '252025-12-310
Q3 '252025-09-300
Q2 '252025-06-300
Q1 '252025-03-310
Q4 '242024-12-31-665K
Q3 '242024-09-30416K
Q2 '242024-06-30-1M
Q1 '242024-03-3188.6M
Q4 '232023-12-31108.4M
Q3 '232023-09-30102.7M
Q2 '232023-06-3098.2M
Q1 '232023-03-3171.4M
Q4 '222022-12-3121.9M
Q3 '222022-09-30345K
Q4 '212021-12-310
Q3 '212021-09-30285K

Gross Profit Quarterly

Revenue minus cost of sales. This filer tags no gross profit of its own..

PeriodEndingGross Profit
Q4 '252025-12-310
Q3 '252025-09-300
Q2 '252025-06-300
Q1 '252025-03-310
Q4 '242024-12-31-665K
Q3 '242024-09-30416K
Q2 '242024-06-30-1M
Q1 '242024-03-3182.7M
Q4 '232023-12-3199.1M
Q3 '232023-09-3097.5M
Q2 '232023-06-3092.6M
Q1 '232023-03-3166.1M
Q4 '222022-12-3119.1M
Q3 '222022-09-30173K

Operating Income Quarterly

PeriodEndingOperating Income
Q2 '262026-06-30-45.7M
Q1 '262026-03-31-43.8M
Q4 '252025-12-31-36.6M
Q3 '252025-09-30-36M
Q2 '252025-06-30-42.9M
Q1 '252025-03-31-37.8M
Q4 '242024-12-31-40.7M
Q3 '242024-09-30-75.7M
Q2 '242024-06-30-76.3M
Q1 '242024-03-31-122.1M
Q4 '232023-12-311.9M
Q3 '232023-09-3018.7M
Q2 '232023-06-3020.2M
Q1 '232023-03-31-2.1M
Q4 '222022-12-31-44.6M
Q3 '222022-09-30-54.7M
Q2 '222022-06-30-54.3M
Q1 '222022-03-31-47.8M
Q4 '212021-12-31-28.3M
Q3 '212021-09-30-22.9M

Net Income Quarterly

PeriodEndingNet Income
Q2 '262026-06-30-43.4M
Q1 '262026-03-31-41.3M
Q4 '252025-12-31-33M
Q3 '252025-09-30-34.4M
Q2 '252025-06-30-41.4M
Q1 '252025-03-31-35.9M
Q4 '242024-12-31-37.5M
Q3 '242024-09-30-72.7M
Q2 '242024-06-30-72.7M
Q1 '242024-03-31-118.8M
Q4 '232023-12-314.7M
Q3 '232023-09-3020.9M
Q2 '232023-06-3022.1M
Q1 '232023-03-311.6M
Q4 '222022-12-31-42.7M
Q3 '222022-09-30-53.8M
Q2 '222022-06-30-54.1M
Q1 '222022-03-31-47.8M
Q4 '212021-12-31-28.3M
Q3 '212021-09-30-23.1M

Cost of Revenue Quarterly

PeriodEndingCost of Revenue
Q4 '252025-12-310
Q3 '252025-09-300
Q2 '252025-06-300
Q1 '252025-03-310
Q4 '242024-12-310
Q3 '242024-09-300
Q2 '242024-06-308K
Q1 '242024-03-315.9M
Q4 '232023-12-319.4M
Q3 '232023-09-305.2M
Q2 '232023-06-305.6M
Q1 '232023-03-315.3M
Q4 '222022-12-312.8M
Q3 '222022-09-30172K

Operating Cash Flow Quarterly

PeriodEndingOperating Cash Flow
Q2 '262026-06-30-31.4M
Q1 '262026-03-31-36.9M
Q4 '252025-12-31-27.9M
Q3 '252025-09-30-30.4M
Q2 '252025-06-30-25.2M
Q1 '252025-03-31-39.8M
Q4 '242024-12-31-59M
Q3 '242024-09-30-41.6M
Q2 '242024-06-30-66.6M
Q1 '242024-03-31-489K
Q4 '232023-12-3113.6M
Q3 '232023-09-30-5.2M
Q2 '232023-06-308.6M
Q1 '232023-03-31-5.1M
Q4 '222022-12-31-49.7M
Q3 '222022-09-30-43.1M
Q2 '222022-06-30-46.5M
Q1 '222022-03-31-40.6M
Q4 '212021-12-31-28.2M
Q3 '212021-09-30-20.9M

Free Cash Flow Quarterly

Operating cash flow minus capital expenditure.

PeriodEndingFree Cash Flow
Q4 '252025-12-31-28M
Q3 '252025-09-30-30.4M
Q2 '252025-06-30-25.3M
Q1 '252025-03-31-39.8M
Q4 '242024-12-31-59M
Q3 '242024-09-30-41.6M
Q2 '242024-06-30-66.7M
Q1 '242024-03-31-556K
Q4 '232023-12-3113.2M
Q3 '232023-09-30-5.5M
Q2 '232023-06-308.3M
Q1 '232023-03-31-5.3M
Q4 '222022-12-31-50.3M
Q3 '222022-09-30-43.5M
Q2 '222022-06-30-47.6M
Q1 '222022-03-31-41M
Q4 '212021-12-31-28.4M
Q3 '212021-09-30-21M
Q2 '212021-06-30-13M
Q1 '212021-03-31-12.7M

Shares Outstanding Quarterly

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

PeriodEndingShares Outstanding
Q2 '262026-06-30111.2M
Q1 '262026-03-31110.6M
Q3 '252025-09-3093.3M
Q2 '252025-06-3089.1M
Q1 '252025-03-3185.7M
Q3 '242024-09-3068.1M
Q2 '242024-06-3068M
Q1 '242024-03-3167.9M
Q3 '232023-09-3069.7M
Q2 '232023-06-3070.1M
Q1 '232023-03-3170.9M
Q3 '222022-09-3058.5M
Q2 '222022-06-3058.3M
Q1 '222022-03-3151.6M
Q3 '212021-09-306.8M
Q2 '212021-06-306.4M

EPS TTM

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.

PeriodEndingEPS
Q2 '262026-06-30-1.41
Q1 '262026-03-31-1.48
Q4 '252025-12-31-1.53
Q3 '252025-09-30-1.79
Q2 '252025-06-30-2.49
Q1 '252025-03-31-3.10
Q4 '242024-12-31-4.43
Q3 '242024-09-30-3.82
Q2 '242024-06-30-2.45
Q1 '242024-03-31-1.07
Q4 '232023-12-310.70
Q3 '232023-09-300.01
Q2 '232023-06-30-1.21
Q1 '232023-03-31-2.45
Q4 '222022-12-31-3.40
Q3 '222022-09-30-6.93
Q2 '222022-06-30-9.43
Q1 '222022-03-31-11.91
Q4 '212021-12-31-13.31